Croda International PLC

Croda International creates, makes, and sells specialty chemicals. Co.'s sales, marketing and research activities are organized into four global market sectors: Personal Care, which focuses on ingredients for skin, hair, sun protection and color cosmetic products; Life Sciences, which comprises of three complementary businesses: Health Care, Crop Protection, and Seed Enhancement; Performance Technologies, which targets technologies in Smart Materials and Energy Technologies and continues to develop its presence in Home Care and Water Treatment; and Industrial Chemicals, which is a sector based on selling co-streams, developing niche industrial applications and undertaking toll processing.
  • TickerCRDA
  • ISINGB00BYZWX769
  • ExchangeLondon Stock Exchange
  • SectorChemicals
  • CountryUnited Kingdom

Analysts

10 directors bought/sold after exercising options/sold

Ten Directors at Croda International bought/sold after exercising options/sold 89,337 shares at between 4,880p and 4,908p. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activi...

Rob Hales

Morningstar | Momentum Shifts Down in 2H for Croda, but Trends Remain Solid; Shares Overvalued

Narrow-moat Croda reported second-half EBIT of GBP 164 million, up 5% over 2017 and in line with consensus but slightly lower than our expectations. The shares traded down after the report as it appears the market was hoping for more growth. Second-half constant-currency growth in the core business was 2.8%, a downward shift from the strong 4.7% growth posted in the first half. Croda doesn’t really do guidance, so commentary on the outlook for 2019 was limited to "further progress." Our current estimates call for a 7% increase in EBIT in 2019, which we don’t expect to change materially, nor do...

Rob Hales

Momentum Shifts Down in 2H for Croda, but Trends Remain Solid; Shares Overvalued

Narrow-moat Croda reported second-half EBIT of GBP 164 million, up 5% over 2017 and in line with consensus but slightly lower than our expectations. The shares traded down after the report as it appears the market was hoping for more growth. Second-half constant-currency growth in the core business was 2.8%, a downward shift from the strong 4.7% growth posted in the first half. Croda doesn’t really do guidance, so commentary on the outlook for 2019 was limited to "further progress." Our current ...

Croda International – Proxinvest Corporate Governance Rating ® : B

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

MarketLine Department

Clariant Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Clariant Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Clariant Ltd. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlig...

Rob Hales

Morningstar | Momentum Shifts Down in 2H for Croda, but Trends Remain Solid; Shares Overvalued

Narrow-moat Croda reported second-half EBIT of GBP 164 million, up 5% over 2017 and in line with consensus but slightly lower than our expectations. The shares traded down after the report as it appears the market was hoping for more growth. Second-half constant-currency growth in the core business was 2.8%, a downward shift from the strong 4.7% growth posted in the first half. Croda doesn’t really do guidance, so commentary on the outlook for 2019 was limited to "further progress." Our current estimates call for a 7% increase in EBIT in 2019, which we don’t expect to change materially, nor do...

Rob Hales

Momentum Shifts Down in 2H for Croda, but Trends Remain Solid; Shares Overvalued

Narrow-moat Croda reported second-half EBIT of GBP 164 million, up 5% over 2017 and in line with consensus but slightly lower than our expectations. The shares traded down after the report as it appears the market was hoping for more growth. Second-half constant-currency growth in the core business was 2.8%, a downward shift from the strong 4.7% growth posted in the first half. Croda doesn’t really do guidance, so commentary on the outlook for 2019 was limited to "further progress." Our current ...

Rob Hales

Morningstar | CRDA Updated Forecasts and Estimates from 14 Jan 2019

We are maintaining our GBX 4,000 fair value estimate for narrow-moat Croda after reviewing the third-quarter trading update. At current levels, the shares look overvalued. Constant currency sales growth was 3.4% for the group and 4.5% in the core business, led by the life sciences segment. This is tracking in line with our expectations for the year. Sales for new, patented, or protected products, or NPP, reached 28.4%. Margins were reported to be slightly ahead of 2017 on a year-to-date basis. Personal care continued to be strong with 4.9% constant currency sales growth in the third quarter o...

Rob Hales

Morningstar | Solid Growth Continues for Croda in 3Q; Shares Overvalued

We are maintaining our GBX 4,000 fair value estimate for narrow-moat Croda after reviewing the third-quarter trading update. At current levels, the shares look overvalued. Constant currency sales growth was 3.4% for the group and 4.5% in the core business, led by the life sciences segment. This is tracking in line with our expectations for the year. Sales for new, patented, or protected products, or NPP, reached 28.4%. Margins were reported to be slightly ahead of 2017 on a year-to-date basis. Personal care continued to be strong with 4.9% constant currency sales growth in the third quarter o...

Rob Hales

Solid Growth Continues for Croda in 3Q; Shares Overvalued

We are maintaining our GBX 4,000 fair value estimate for narrow-moat Croda after reviewing the third-quarter trading update. At current levels, the shares look overvalued. Constant currency sales growth was 3.4% for the group and 4.5% in the core business, led by the life sciences segment. This is tracking in line with our expectations for the year. Sales for new, patented, or protected products, or NPP, reached 28.4%. Margins were reported to be slightly ahead of 2017 on a year-to-date basis. ...

10 directors bought/sold after exercising options/sold

Ten Directors at Croda International bought/sold after exercising options/sold 89,337 shares at between 4,880p and 4,908p. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activi...

CRODA INTERNATIONAL PLC. sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of CRODA INTERNATIONAL PLC. (GB), active in the Specialty Chemicals industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date October 19, 2018, the closing price was GBp 4,722.00 and its target price was estimated at GBp 4,485.90.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

Clariant Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Clariant Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Clariant Ltd. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlig...

Croda International – Proxinvest Corporate Governance Rating ® : B

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 26/04/2017

Item 3: Approve the remuneration report. The structure is generally acceptable, though there is concern with the possibility for accelerated vesting of the LTIP. Variable remuneration has the potential to be excessive, but was not during the year. However, the annual bonus only uses one performance metric and targets are not disclosed so it is unclear whether the bonus adequately aligns pay with performance.Item 13: Re-appoint the auditors. PricewaterhouseCoopers LLP (PwC) has been the external auditors of the Group since 1970. The tenure of the auditors is extremely long, which clearly may un...

Valérie GASTALDY

Analyse court terme - CRODA INTERNATIONAL PLC : La tendance est incertaine.

La tendance est incertaine. Les cours baissent, mais la tendance manque de puissance pour le moment. Le prochain support est à 4 332,38 p.

Valérie GASTALDY

Short term view - CRODA INTERNATIONAL PLC : The trend is uncertain.

The trend is uncertain. Prices are falling, but the trend is lacking power for the time being. The next support is at 4,332.38 p.

Valérie GASTALDY

Short term view - CRODA INTERNATIONAL PLC : The trend is bearish.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at 4,332.38 p. The bearish trend would be challenged above 5,330.00 p.

Valérie GASTALDY

Analyse court terme - CRODA INTERNATIONAL PLC : La tendance est baissière.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 4 332,38 p. La tendance baissière serait remise en cause au-dessus de 5 330,00 p.

Valérie GASTALDY

Analyse moyen terme - CRODA INTERNATIONAL PLC : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. La correction en cours gagne en vigueur. Il est trop tôt pour parler de retournement baissier. La tendance serait invalidée sous le support à 4 661,27 p.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch